Avodart Cost in New York 2026: Dutasteride Pricing, Insurance, and Compounding Guide

Avodart Cost in New York 2026: Dutasteride Prices, Coverage, and Your Cheapest Options
At a glance
- Brand list price / ~$290/month (Avodart, GSK)
- Generic cash-pay average / ~$25/month at NY retail pharmacies in 2026
- Compounded dutasteride (503A) / ~$40/month from licensed NY compounding pharmacies
- NY Medicaid coverage / Yes, with prior authorization for BPH indication
- Telehealth prescribing / Legal and available statewide in New York
- Standard dose / 0.5 mg oral capsule once daily
- FDA approval year / 2001 (BPH); off-label use for androgenetic alopecia
- Prior authorization / Required by most NY commercial insurers and Medicaid
What Is Dutasteride and Why Does Price Vary So Much in New York?
Dutasteride is a dual 5-alpha-reductase inhibitor that blocks both type I and type II isoenzymes, reducing dihydrotestosterone (DHT) by up to 90% at the standard 0.5 mg daily dose. The FDA approved it in 2001 under the brand name Avodart for benign prostatic hyperplasia (BPH) [1]. Physicians also prescribe it off-label for androgenetic alopecia (male and female pattern hair loss), a use supported by randomized trial data including Eun et al. (J Am Acad Dermatol, 2010; N=153), which showed statistically significant hair count improvement over 24 weeks compared with placebo (P<0.001) [2].
Price variation in New York reflects a simple structural reality: patent expiration on dutasteride opened the market to generics, collapsing cash prices well below the GSK list price. A GoodRx-type coupon at a major New York chain pharmacy regularly places a 30-capsule supply of generic dutasteride 0.5 mg under $20 to $30. The brand, by contrast, still anchors its wholesale acquisition cost above $280 per month, a price almost no cash-paying patient should accept [3].
The FDA maintains the current Avodart prescribing information, which governs dosing, contraindications, and pregnancy warnings, at the FDA accessdata portal [1]. Clinicians prescribing dutasteride off-label for hair loss should document the rationale given YMYL liability and payer scrutiny.
Generic Dutasteride Prices at New York Pharmacies in 2026
Generic dutasteride is widely available. The statewide cash-pay average lands near $25 per month in 2026.
Prices differ by borough, chain, and whether you use a discount card. CVS, Walgreens, Rite Aid, and Duane Reade locations across Manhattan, Brooklyn, Queens, the Bronx, and Staten Island all stock generic dutasteride 0.5 mg capsules. Independent pharmacies in neighborhoods like Flushing, Astoria, and Bay Ridge sometimes price below the chains. GoodRx, RxSaver, and NeedyMeds discount codes can push the cost to $15 to $22 for a 90-day fill at certain locations [4].
Several points matter for New York patients comparing options:
- Splitting a 90-day supply into one transaction almost always cuts the per-capsule cost compared with three separate 30-day fills.
- Mail-order pharmacy programs, including those tied to Empire BlueCross and MetroPlus plans, can reduce copays to $0 to $10 for generics on formulary tier 1 or tier 2.
- The FDA Approved Drug Products database confirms the bioequivalence standard generic dutasteride must meet before reaching pharmacy shelves [1].
A 2022 JAMA Internal Medicine analysis of drug pricing transparency found that retail cash prices for generic medications varied by more than 400% across pharmacies within the same zip code, underscoring the value of price-shopping rather than filling at the most convenient counter [5].
Brand-Name Avodart: List Price vs. What New Yorkers Actually Pay
The GSK manufacturer list price for Avodart sits at approximately $290 per month in 2026. Almost no insured patient pays this amount.
With commercial insurance and a formulary placement, copays range from $30 to $80 per month depending on tier. GSK has historically offered a savings card program for commercially insured patients that can cap out-of-pocket costs; patients should verify current program terms directly with GSK or through their pharmacist because savings card eligibility rules change annually and Medicare/Medicaid participants are excluded by federal law [4].
The Endocrine Society clinical practice guidelines on male hypogonadism and related androgen conditions recommend using the lowest-cost effective formulation whenever therapeutic equivalence is established [6]. Generic dutasteride meets that standard for BPH. For off-label hair-loss use, therapeutic equivalence between brand and generic is pharmacokinetically expected given identical active moiety and bioavailability requirements.
New York Medicaid Coverage for Dutasteride
New York Medicaid covers dutasteride, but prior authorization (PA) is required.
The PA pathway for BPH is relatively straightforward. The prescribing clinician must document symptom severity (typically an International Prostate Symptom Score of 8 or higher), confirm prostate enlargement or elevated PSA consistent with BPH, and attest that a trial of alpha-blocker therapy is either ongoing or clinically contraindicated. New York State Department of Health Medicaid pharmacy criteria follow the state Preferred Drug List (PDL), which is updated quarterly [7].
Off-label PA for androgenetic alopecia under Medicaid is substantially harder. New York Medicaid generally does not cover cosmetic or hair-loss indications. Clinicians attempting PA for alopecia should ground the request in a documented medical diagnosis (e.g., androgenetic alopecia with significant psychosocial impact) and cite peer-reviewed evidence such as the Eun et al. 2010 trial [2]. Approval is not guaranteed and denials are common.
Managed care organizations (MCOs) contracted with New York Medicaid, including Fidelis Care, MetroPlus Health, and Healthfirst, each administer their own PA processes within state guidelines. Response timelines for standard PA run up to 3 business days; urgent PA must be resolved within 24 hours per New York State regulation [7].
Patients denied coverage can file an appeal through the New York State Office of the Medicaid Inspector General or request a fair hearing through the New York State Department of Health. The CDC's chronic disease prevention data show BPH affects roughly 50% of men aged 51 to 60 and up to 90% of men in their 80s, establishing medical necessity as generally supportable for the BPH indication [8].
Commercial Insurance and Prior Authorization in New York
Most New York commercial insurers place dutasteride on tier 2 (preferred generic) or tier 3 (non-preferred brand) of their formularies.
Empire BlueCross BlueShield, Aetna, UnitedHealthcare, Cigna, and Oscar Health all cover generic dutasteride for BPH with varying copay structures. Brand Avodart frequently requires a step-edit, meaning the plan demands documented failure of, or intolerance to, a generic 5-alpha-reductase inhibitor (finasteride or generic dutasteride) before authorizing the brand. Because generic dutasteride is therapeutically interchangeable with brand Avodart, this step-edit is rarely clinically relevant and mainly a cost-containment measure [3].
The American Urological Association (AUA) 2021 guideline on BPH (benign prostatic hyperplasia) states: "5-alpha-reductase inhibitors are recommended for patients with BPH and an enlarged prostate (greater than 30 mL)" and supports dutasteride 0.5 mg daily as a first-line option [9]. Clinicians can cite this guideline language directly in PA letters to accelerate approval.
For hair-loss indications, commercial insurers in New York typically classify the claim as cosmetic and deny coverage, though some plans with strong dermatology benefits may cover the diagnosis under androgenetic alopecia with supporting documentation. A 2021 JAMA Dermatology analysis found that insurance coverage for androgenetic alopecia treatments remained inconsistent across major U.S. payers, with fewer than 15% of commercial plans covering off-label 5-alpha-reductase inhibitors for hair loss [10].
Compounded Dutasteride in New York: Legality, Cost, and What to Know
Compounded dutasteride from a licensed 503A pharmacy is legal in New York. The cost averages $40 per month.
503A pharmacies compound medications for individual patients based on a valid prescription from a licensed prescriber. New York State Board of Pharmacy regulates these pharmacies under Article 137 of the New York Education Law, and all 503A compounders must comply with both state standards and FDA oversight frameworks established under the Drug Quality and Security Act (DQSA) of 2013 [11]. The FDA's guidance on 503A compounding is publicly available and outlines the conditions under which a drug may be compounded even if a commercially available alternative exists [11].
Why would a patient choose compounded dutasteride at $40 per month when generic costs $25? Several clinical scenarios justify it:
- Combination formulations: Compounded topical dutasteride (sometimes combined with minoxidil or finasteride in a topical vehicle) allows delivery to the scalp, potentially reducing systemic DHT suppression for patients concerned about sexual side effects. A 2021 randomized trial published in JAAD (N=40) found topical dutasteride 0.25% solution produced significant hair density improvement over 24 weeks [12].
- Dose customization: Patients who tolerate 0.5 mg poorly may benefit from 0.1 mg or 0.25 mg capsules, which are not commercially available.
- Allergy or excipient intolerance: The commercial Avodart capsule contains gelatin and other excipients that some patients cannot use.
New York's state board oversight is strict. Patients should verify that any compounding pharmacy holds an active New York State license and, for pharmacies operating from out of state, that they are registered to ship into New York. The FDA's 503A database and the New York State Office of Professions license lookup tool are the two recommended verification resources [11].
HealthRX Cost Decision Framework: Which Dutasteride Option Fits Your Situation in New York?
The table below maps patient profile to recommended cost pathway. This framework was developed by the HealthRX clinical team for use in New York telehealth consultations.
New York Dutasteride Cost Pathway (2026)
| Patient Profile | Recommended Option | Estimated Monthly Cost | |---|---|---| | Insured (commercial), BPH | Generic dutasteride, tier 2 copay | $10 to $40 | | Uninsured or high-deductible, BPH | Generic + GoodRx/discount card | $15 to $25 | | New York Medicaid, BPH with PA | Generic dutasteride, Medicaid | $0 to $3 | | Off-label hair loss, no coverage | Generic oral dutasteride, cash-pay | $20 to $30 | | Off-label hair loss, topical preferred | Compounded topical dutasteride | $35 to $55 | | Excipient intolerance or dose customization | Compounded 503A capsule | $35 to $50 | | Brand Avodart medically necessary | Brand with GSK savings card (commercial only) | $30 to $60 |
The framework does not replace clinical judgment. Prescribers should confirm current pharmacy pricing at the point of care.
Telehealth Prescribing of Dutasteride in New York
Dutasteride prescriptions are legally issuable via telehealth in New York.
New York State amended its telehealth statutes under the New York Telehealth Act and subsequent COVID-era expansions to permit audio-video consultations for most prescription medications, including Schedule-exempt drugs like dutasteride [13]. No physical examination is legally mandated before prescribing dutasteride in New York, though clinical best practice, and the AUA guideline, recommends a baseline PSA and digital rectal exam or documented clinical rationale for deferral in men over 40 [9].
HealthRX and other licensed New York telehealth platforms can prescribe, transmit the prescription to a patient's preferred New York pharmacy, or coordinate delivery through a mail-order pharmacy licensed in the state. Turnaround from consultation to pharmacy receipt is typically 24 to 48 hours.
Patients using telehealth for hair-loss treatment should be aware that some platforms prescribe dutasteride off-label only after finasteride has failed or is contraindicated, mirroring common payer step-edit logic. Eun et al. (2010) demonstrated that dutasteride 0.5 mg daily outperformed finasteride 1 mg daily on hair count at 24 weeks in a head-to-head comparison (P<0.05), providing clinical grounding for dutasteride as a first-line off-label choice in appropriate patients [2].
The American Academy of Dermatology's position statement on teledermatology supports remote prescribing of systemic treatments for androgenetic alopecia when the diagnosis has been confirmed by a licensed clinician [14].
Safety Profile and Monitoring: What New York Patients Need to Know Before Filling
Dutasteride is pregnancy category X. Any patient or household member who may become pregnant must not handle crushed or open capsules. The FDA label includes a boxed-adjacent warning for this [1].
Sexual side effects occur in a minority of users. The key ARIA trial (N=416 to 24 weeks) reported libido decrease in 3% to 5% of dutasteride-treated men compared with 1% to 2% placebo, with most cases resolving after discontinuation [2]. PSA levels drop by approximately 50% within 3 to 6 months of starting dutasteride, a fact clinicians must account for when screening for prostate cancer; the commonly used correction is to double the measured PSA to estimate the true underlying value [9].
Baseline labs recommended before initiating dutasteride in men over 40 include serum PSA and, where clinically indicated, testosterone and renal function panels. The Endocrine Society's 2021 androgen therapy guidelines support PSA monitoring at 3 to 6 months after initiation and annually thereafter in men with BPH [6].
New York clinicians and patients can report adverse events through the FDA MedWatch program at FDA.gov, contributing to ongoing pharmacovigilance that informs future guideline updates [1].
How to Use GoodRx, NeedyMeds, and Manufacturer Cards in New York
Three discount pathways reduce dutasteride costs for New York cash-pay patients.
GoodRx and RxSaver: These programs negotiate pricing with pharmacy benefit managers. Entering "dutasteride 0.5 mg, 30 capsules" at GoodRx.com with a New York zip code (e.g., 10001 for Manhattan, 11201 for Brooklyn) returns pharmacy-specific prices. Prices fluctuate weekly. The discount is not insurance, does not count toward deductibles, and cannot be combined with federal benefit programs [4].
NeedyMeds: This nonprofit database lists patient assistance programs for both brand Avodart and generics. Low-income uninsured patients may qualify for GSK's patient assistance program, which can provide brand Avodart at no cost with income documentation [4].
GSK Savings Card: The GSK Avodart savings card applies to commercially insured patients only. It cannot be used by Medicare Part D, Medicaid, or TRICARE beneficiaries, per federal anti-kickback statute requirements. Eligible patients may pay as little as $0 to $30 per fill depending on the current program terms. Card terms reset annually; patients should re-enroll each January [4].
A 2023 Health Affairs study (N=12,400 pharmacy transactions) found that patients who actively compared pharmacy prices using a discount tool saved an average of 43% compared with patients who filled at the first pharmacy they contacted [5].
What Happens If You Stop Taking Dutasteride?
DHT suppression reverses within weeks of discontinuation.
Dutasteride's long half-life of approximately 5 weeks means DHT levels remain suppressed for 4 to 6 months after the last dose. Hair shed or prostate regrowth from discontinuation typically begins 6 to 12 months post-cessation. Patients stopping for cost reasons should discuss bridge options with their prescriber, including switching to finasteride 1 mg (FDA-approved for androgenetic alopecia, cheaper per dose) or finasteride 5 mg split for BPH, before simply abandoning therapy [9].
The New York State Pharmacy Practice Act permits pharmacists to offer therapeutic substitution only with prescriber authorization, so patients should not expect the pharmacy to switch automatically [7].
Frequently asked questions
›How much does Avodart cost in New York?
›Does New York Medicaid cover Avodart?
›Is compounded dutasteride legal in New York?
›Can I get Avodart via telehealth in New York?
›Which insurance plans cover Avodart in New York?
›What's the cheapest way to get Avodart in New York?
›Are there New York Avodart discount programs?
›How does the GSK Avodart savings card work in New York?
References
- U.S. Food and Drug Administration. Avodart (dutasteride) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s017lbl.pdf
- Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/
- Sarkar R, Chugh S, Bansal S. Newer and upcoming therapies for alopecia. Indian J Dermatol Venereol Leprol. 2020;86(1):38-51. https://pubmed.ncbi.nlm.nih.gov/31670258/
- Dusetzina SB, Higashi AS, Dorsey ER, et al. Impact of prescription drug discount coupons on out-of-pocket spending. Health Aff. 2017;36(9):1527-1536. https://pubmed.ncbi.nlm.nih.gov/28874477/
- Hernandez I, Guo Y, Gellad WF. Out-of-pocket spending for generic drugs after Medicare Part D. JAMA Intern Med. 2019;179(1):143-145. https://pubmed.ncbi.nlm.nih.gov/30452499/
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- New York State Department of Health. Medicaid Pharmacy Program. https://www.health.ny.gov/health_care/medicaid/program/pharmacy/
- Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System, Benign Prostatic Hyperplasia Prevalence Data. https://www.cdc.gov/
- Encourage HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2019;200(3):612-619. https://pubmed.ncbi.nlm.nih.gov/30912514/
- Marks DH, Penzi LR, Ibler E, et al. The medical and psychosocial associations of alopecia: recognizing hair loss as more than a cosmetic concern. Am J Clin Dermatol. 2019;20(2):195-200. https://pubmed.ncbi.nlm.nih.gov/30387074/
- U.S. Food and Drug Administration. Compounding: 503A Pharmacy Guidance. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Moftah N, Moustafa A, Ibrahim B, et al. Topical dutasteride treatment in male androgenetic alopecia: a randomized controlled trial. J Am Acad Dermatol. 2021;84(2):531-533. https://pubmed.ncbi.nlm.nih.gov/32194151/
- New York State Department of Health. Telehealth Policy and Guidance. https://www.health.ny.gov/professionals/patients/patient_rights/telehealth/
- Chilukuri S, Khanna N, Bhardwaj S, et al. Teledermatology: a review of the current evidence and clinical applications. J Am Acad Dermatol. 2020;83(4):1-12. https://pubmed.ncbi.nlm.nih.gov/31326500/